Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

.3 mg/m2 on days 1, 4, 8 and 11, and dexamethasone at 40 mg on days 1 through 4, 9 through 12, and 17 through 20 of a 28-day schedule. A total of four cycles was planned with a goal of proceeding on to stem cell transplant (SCT). Results were presented by Craig Reeder, M.D., Assistant Professor of Medicine, Mayo Clinic College of Medicine, and showed a CR rate of 46 percent prior to transplant, a CR rate of 72 percent post-transplant and an overall response rate (partial response or better) of 95 percent. Side effects included thrombocytopenia, neutropenia, hyperglycemia and peripheral neuropathy.

VELCADE, Pegylated-Lyposomal-Doxorubicin and dexamethasone (PAD or VcDD) as Induction Therapy Prior to Reduced Intensity ASCT Followed by Lenalidomide and Prednisone (LP) as Consolidation and Lenalidomide Alone as Maintenance (Abstract #8518)

This study of PAD (VcDD) was designed to evaluate the VELCADE combination as induction therapy prior to SCT in patients with newly diagnosed multiple myeloma. The results showed the status of 86 evaluable patients who received VELCADE at 1.3 mg/m2 on days 1, 4, 8, 11, DOXIL at 30 mg/m2 on day 4 and dexamethasone at 40 mg on days 1 through 4, 8 through 11, 15 through 18 for one cycle and on days 1 through 4 for cycles two through four. Cyclophosphamide at 3 g/m2 and G-CSF were used to harvest stem cells. Patients were then conditioned with two courses of melphalan at 100 mg/m2 (MEL100). Following SCT, patients received lenalidomide at 25 mg/day on days 1 through 21 plus prednisone at 50 mg every other day for four, 28-day LP cycles. This was followed by lenalidomide alone at 10 mg/day on days 1 through 21 every 28 days. Results were presented by Antonio Palumbo, M.D., Chief of the Myeloma Unit; Department of Hematology, University of Torino and showed 94 percent of patients achieved at least a partial response, including a CR rate of 21 percent after four cycles of VcDD. Post transplant, the CR rate increased to 59 percen
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... to release its second quarter 2011 financial results on Tuesday, ... financial markets.  The Company will also host a conference call ... 2011 to discuss its financial results and provide an update ...
... CHADDS FORD, Pa., June 30, 2011 Endo Pharmaceuticals (Nasdaq: ... phase 2 study comparing the novel investigational drug axomadol against ... chronic low back pain. The results indicate that axomadol did ... completing additional analyses of the data and evaluating the path ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings 2Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:The ilk of human kindness 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:New MRSA superbug emerges in Brazil 2
... who eat fish or seafood at least once a week have ... studied a group of 1205 people aged over 65 //and without ... consuming meat, fish and seafood, then followed them up to, five ... seafood at least once a week had a significantly lower risk ...
... the latest study done by the researchers of University of ... the cause if you have abdominal pain, gas and diarrhea.// ... and diarrhea and no obvious reason can be found. They ... with these symptoms may be unable to digest fructose. ...
... study it is indicative that systolic blood pressure is ... with impaired consciousness. This means doctors may now have ... using expensive and time-consuming imaging technology. ,Researchers studied ... to an emergency room with impaired consciousness. Of the ...
... University observed that anomalies in the part of the brain ... Recent studies have linked facial// recognition to a part of ... both the left and right sides of the brain. This ... seeing and also what they may be thinking or feeling ...
... for early outset glaucoma appears to slow the advancement of ... form of glaucoma appears to impact the progression of vision ... to detect it only in a detailed eye exam. In ... glaucoma in one eye. Around half of the group was ...
... to a new study it is observed that reducing blood ... half. It is already known that hypertension (high blood pressure) ... a study carried out by doctors in Dallas, the effect ... ,A group of patients with systolic hypertension - ...
Cached Medicine News:
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio...
... is a method for isolating antibodies, ... cells using affinity binding, while retaining ... on the particles to separate biotinylated ... the MagnaBind™ Beads from the suspension, ...
... m Dynabeads with covalently bound ... any biotinylated target. The Dynabeads® ... area, high capacity, magnetic pull ... during incubation. The MyOne™ products ...
Medicine Products: